Abstract:The genetic basis of antipsychotic drug efficacy is likely polygenic in nature. Genetic risks of schizophrenia may also be related to antipsychotic drug response. The Psychiatric Genomics Consortium (PGC) Genome-Wide Association Study (GWAS) provided evidence of association with schizophrenia risk for many Single Nucleotide Polymorphism (SNP) across the genome. We examined whether Polygenic Risk Scores (PRS) based on the PGC GWAS are predictive of antipsychotic efficacy in four cohorts of patients with first episode psychosis (total n=510): 1) Zucker Hillside Hospital First Episode schizophrenia trial (ZHH-FE), 2) European First Episode Schizophrenia Trial (EUFEST), 3) Spanish First Episode Psychosis study (SFEP), and 4) the clinical trial as part of the Center for Intervention Development and Applied Research at ZHH (CIDAR). The discovery cohort was the ZHH-FE with 77 patients (mixed ethnicity) randomized to risperidone or olanzapine. Three replication cohorts were: 1) EUFEST with 141 patients (all Caucasian) randomized to five antipsychotics; 2) SFEP with 192 patients (all Caucasian) on various antipsychotics; and 3) CIDAR with 100 patients (mixed ethnicity) randomized to risperidone or aripiprazole. Genotyping was performed using the Illumina Omni-1Quad (EUFEST and ZHH-FE) or Illumina Infinium HumanOmniExpressExome platform (CIDAR and SFEP). SNP imputation was conducted with IMPUTE2 against the full 1000 Genomes v3 reference panel. PRS was computed based on the results of the PGC GWAS using PRSice software for the discovery cohort with thresholds at PT<5E-8, 0.001, 0.01, 0.05, 0.10, 0.20, 0.50. Based on the findings from the discovery cohort, PRS was computed for the three replication cohorts using a threshold of PT<0.01. Symptom measure was the total score of Brief Psychiatric Rating Scale (BPRS) for ZHH-FE, SFEP, and CIDAR, or Positive and Negative Symptoms Scale (PANSS) for EUFEST. Hierarchical linear regression was performed on the 3-month symptom score with the PRS as the predictor while controlling for age, sex, and baseline symptom score. Genomic principal component scores were also covaried to control for population stratification for ZHH-FE and CIDAR. In the ZHH-FE cohort, higher PRS at the thresholds of PT<0.01, 0.05, 0.10, 0.20, and 0.50 significantly predicted higher symptom scores at 3-month follow-up, explaining 6–8% of the variance (all p's<0.05). PT<0.01 gave the strongest result in the discovery sample, and was used to replicate the findings in the other three cohorts. Higher PRS significantly predicted worse symptoms in EUFEST and SFEP cohorts, explaining 3.5% and 3.7% of variance, (p's<0.01), but not in the CIDAR sample. Combining the four cohorts in a meta-analysis, PRS was significantly predictive of 3-month symptom scores (pooled partial r=0.18, p=0.002). Higher PRS was associated with higher symptom scores at 3-month follow-up, suggestive of less improvement in treatment. The overall results remained significant when only European ancestry individuals were included in the analysis. These findings suggest that polygenic risk scores for schizophrenia may also be related to antipsychotic drug response. Patients with higher polygenic risk scores tended to have less improvement with antipsychotic drug treatment. Further analysis is needed to elucidate a more refined genomic profile for antipsychotic drug response.

Gene expression imputation provides clinical and biological insights into treatment-resistant schizophrenia polygenic risk

Gene expression imputation across multiple brain regions provides insights into schizophrenia risk

Genome-wide association analysis of treatment resistant schizophrenia for variant discovery and polygenic assessment

SCHIZOPHRENIA POLYGENIC RISK SCORE PREDICTS ANTIPSYCHOTIC TREATMENT RESPONSE IN PATIENTS WITH FIRST EPISODE PSYCHOSIS

Imputed Gene Expression versus Single Nucleotide Polymorphism in Predicting Gray Matter Phenotypes.

Gene Expression Elucidates Functional Impact of Polygenic Risk for Schizophrenia

Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study

Increased Schizophrenia Family History Burden and Reduced Premorbid IQ in Treatment-Resistant Schizophrenia: a Swedish National Register and Genomic Study

Transcriptomic risk scores for attention deficit/hyperactivity disorder

Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates

Brain transcriptome-wide association study implicates novel risk genes underlying schizophrenia risk

Shared polygenic susceptibility to treatment response in severe affective and psychotic disorders: Evidence from GWAS data sets

T-SEM of 11 Major Psychiatric Disorders: Identification of Gene Expression Patterns for Cross-Disorder Risk and Drug Repurposing

Identification of novel functional brain proteins for treatment-resistant schizophrenia: Based on a proteome-wide association study

Transcriptome-Wide Structural Equation Modeling of 13 Major Psychiatric Disorders for Cross-Disorder Risk and Drug Repurposing

Gene expression in patient-derived neural progenitors provide insights into neurodevelopmental aspects of schizophrenia

Polygenic risk scores mediating functioning outcomes through cognitive and clinical features in youth at family risk and controls

Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses

Prediction of antipsychotics efficacy based on a polygenic risk score: a real-world cohort study

Integrated Transcriptome Analysis Reveals Novel Molecular Signatures for Schizophrenia Characterization.

The impact of common variants on gene expression in the human brain: from RNA to protein to schizophrenia risk